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PCN5
SOFRAFENIB VERSUS SUNITINIB IN METASTATIC RENAL CELL 
CARCINOMA: INDIRECT COMPARISON ANALYSIS
Leung HW1, Chan AL2
1Taipei Medical University- Shuang Ho Hospital, Taipei, Taiwan; 2Chi Mei Medical Center, 
Tainan, Taiwan
OBJECTIVES: To evaluate the clinical effectiveness of sorafenib and sunitinib in 
metastatic renal cell carcinoma (RCC) by using indirect comparison meta-analysis. 
METHODS: Systematic literature search of Medline, Embase, Cochrane controlled 
trials register. All randomized clinical trials of sorafenib or sunitinib versus interferon 
alfa for treating metastatic renal-cell carcinoma were included. Study selection, data 
extraction and quality assessment were performed by two reviewers with disagree-
ments being resolved by consensus. The effects of sorafenib and sunitinib on progres-
sion-free survival were compared indirectly using indirect treatment comparison 
program, with interferon alfa (IFN) as a common comparator. RESULTS: Two studies 
were included. Median progression-free survival was prolonged with the treatment of 
sunitinib (11 months) compared to interferon alfa (5 months). For the comparison of 
sorafenib and interferon-alfa, the median progression-free survival was similar 
(median PFS: 5.7 months vs. 5.6 months). Indirect comparison suggests that sunitinib 
is not superior to sorafenib for prolongation of progress free survival (hazard ratio 
0.37; 95% CI: 0.236–0.58, P = 0.0189). CONCLUSIONS: There is no signiﬁ cant 
evidence to suggest that treatment with sunitinib has clinical advantages over treat-
ment with sorafenib in patients with metastatic RCC. 
PCN6
RISK OF BREAST CANCER AMONG USERS OF POSTMENOPAUSAL 
HORMONE REPLACEMENT THERAPY IN TAIWAN
Shen WC1, Lin MS2, Bai CH3, Chen WC4, Tang CH4
1Taipei Medical University and Wan Fang Hospital, Taipei, Taiwan; 2National Taiwan 
University and National Taiwan University Hospital, Taipei, Taiwan; 3Taipei Medical 
University/Shin Kong WHS Memorial Hospital, Taipei, Taiwan; 4Taipei Medical University, 
Taipei, Taiwan
OBJECTIVES: To determine whether the association between the different dosage of 
hormone replacement therapy (HRT) and the incidence of breast cancer (BC) in 
postmenopausal women with HRT formulation. METHODS: Patients who had at least 
one outpatient visit for postmenopausal syndrome (ICD-9-CM code 627) with estrogen 
prescription in Taiwan National Health Insurance (NHI) claims database during 1999–
2006 were identiﬁ ed as the study cases. There were 883,052 women identiﬁ ed from the 
dataset. The index date was deﬁ ned as the date of the ﬁ rst menopausal visit with estrogen 
prescription during the study period. To identify any BC events, each case was tracked 
from the index date until December 31, 2006 or death, whichever came ﬁ rst. Women 
without events were censored on December 31, 2006. Survival analysis was performed 
to assess whether cumulative estrogen dosage and combined progesterone were inde-
pendent risk factors of BC. RESULTS: A total of 5524 cases of BC were identiﬁ ed during 
the study period. Women with higher dosage of estrogen had signiﬁ cantly higher risk 
of BC than women with lower dosage (HR = 2.23; P < 0.0001). The risk of BC was 
even higher when progesterone was combined with estrogen (HR = 1.08; P = 0.036). 
Women aged 60–69 (HR = 0.87, P = 0.002) and >70 (HR = 0.66, P < 0.0001) had 
lower risk of BC, compared with women aged <60. Women living in the northern part 
of Taiwan and in areas with higher urbanization level had higher risk of BC, compared 
with their counterparts. CONCLUSIONS: Hormone replacement therapy in post-
menopausal women seemed to be associated with an increased risk of BC. 
PCN7
ESTIMATION ON THE INCIDENCE OF SELECTED CANCERS IN CHINA, 
2004
Li R1, Hu SY2, Lin M3, Wang D4, Dong P4
1Dalian Medical University, Dalian; Cancer Institute, Chinese Academy of Medical Sciences & 
Peking Union Medical College, Beijing, China; 2Institute of Basic Medical Sciences; Cancer 
Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; 
3Washington University in St. Louis, US; Cancer Institute, Chinese Academy of Medical 
Sciences, Peking Union Medical College, Beijing, China; 4Pﬁ zer China, Beijing, China
OBJECTIVES: This study is to investigate the characteristics on incidence of stomach, 
lung, liver, breast and kidney cancer, and to estimate the total number of new cancer 
cases in China in 2004. METHODS: Incidence data were collected through 37 local 
cancer registries across 19 provinces and autonomous regions in China, 2004. Data 
were classiﬁ ed by ICD-10 and processed according to international cancer registration 
guidelines. The number of new cancer cases was estimated by local cancer registry 
data, residence population in the corresponding areas, and the population of China 
in 2004. RESULTS: Registry data covered a population of 57,698,672 residents, 
accounting for 4.44% of Chinese population in 2004. There were 73,552 new cancer 
cases registered, with world age-adjusted incidence by cancer type ranging from 2.69 
per 100,000 to 31.55 per 100,000. Overall, lung cancer was highest in incidence rate, 
followed by cancer of stomach, liver and breast, while kidney cancer accounted for a 
relatively small proportion. Cancer among urban residents by incidence per 100,000 
was lung (33.19), stomach (18.22), breast (16.52), liver (15.83) and kidney (3.32), 
while in rural residents was stomach (40.35), liver (28.66), lung (26.30), breast (6.19), 
and kidney (0.68). Cancer in men by incidence per 100,000 was lung (44.21), stomach 
(33.32), liver (28.94) and kidney (3.50), while in women was breast (27.76), lung 
(19.98), stomach (14.06), liver (8.97) and kidney (1.94). Total cancer incidence was 
estimated 30,571,904 in china in 2004. Estimation of cancer incidence of stomach, 
lung, liver, breast and kidney was 10,609,682, 7,335,176, 5,927,478, 2,492,148, and 
376,927, respectively. CONCLUSIONS: Cancer incidence rates vary by region and 
gender in China. The overall burden of cancer is heavy and more attention should be 
paid to cancer prevention and control. 
CANCER – Cost Studies
PCN8
IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA 
PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A 
COMMERCIALLY INSURED POPULATION IN THE UNITED STATES
Tsong W1, Singer ME2, Ray S1
1Abbott Laboratories, Abbott Park, IL, USA; 2Case Western Reserve University School of 
Medicine, Cleveland, OH, USA
OBJECTIVES: Although hepatocellular carcinoma (HCC) is a highly prevalent disease 
in East Asia with a growing incidence in the US, there is a limited understanding of 
health-care procedures and their economic impact. This study identiﬁ es the procedures 
with the highest payer budget impact in a commercially insured US population. 
METHODS: The MEDSTAT insurance claims database (January 1, 2000–December 
31, 2008) was used to identify a cohort of patients with > = 1 HCC claim (index = 
ﬁ rst claim), age > = 18, and no other cancer diagnoses. For each procedure code, all 
payments (2009 USD) were summed across the cohort and divided by the total patient-
months to estimate the per patient-month (PM) cost. The PM costs were ranked to 
identify procedures with the highest payer budget impact. The proportion of patients 
utilizing each procedure was calculated to evaluate whether PM costs were driven by 
a minority of patients. RESULTS: The study sample included 2927 patients: mean age 
50.4 years, 57% male, and median 9 months follow-up. The inpatient procedures with 
the highest budget impact were: liver transplant and/or intestinal transplant ($526/
PM, 4.6% of patients), tracheostomy with mechanical ventilation ($204/PM, 0.2%), 
disorders of liver except malignancy/cirrhosis/alcoholic hepatitis ($96/PM, 5.1%). For 
hospital outpatient procedures, they were: magnetic resonance imaging (MRI) of the 
abdomen ($18/PM, 15%), computed tomography of abdomen ($13/PM, 17%), and 
transcatheter occlusion/embolization ($8/PM, 4%). For ofﬁ ce outpatient procedures, 
they were: low complexity visits ($26/PM, 70%), moderate complexity visits ($18/
PM, 18%), and MRI of abdomen ($8/PM, 7%). Patients with > = 1 sorafenib prescrip-
tion (<2% of cohort) had a minimal impact on the results. CONCLUSIONS: The key 
procedures with the highest budget impact appear to be related to both cancer and 
liver disease. These costs may be reduced with improved anticancer therapy which 
provides better cancer control and reduces the exacerbation of liver disease from 
tumor growth. 
PCN9
FIRST YEAR MEDICAL CARE COSTS ASSOCIATED WITH 
HEPATOCELLULAR CARCINOMA IN A MEDICAID POPULATION
Tsong W1, White LA2, Ray S1
1Abbott Laboratories, Abbott Park, IL, USA; 2Boston Health Economics, Waltham, MA, USA
OBJECTIVES: Although hepatocellular carcinoma (HCC) is highly prevalent in East 
Asia with a growing incidence in the United States, the economic impact of the disease 
has not been extensively studied. This study compares medical costs of HCC patients 
in the ﬁ rst year after diagnosis with those of non-cancer controls. METHODS: A 
Medicaid database (July 1, 2001–June 30, 2007) was used to identify cases with > = 
1 HCC claim, > = 1 HCC post-index claim, and no other cancers. Controls were 
matched on age, sex, and race. Costs (2008 USD) for medical care services (inpatient, 
outpatient, emergency room [ER], long-term care [home health, nursing home, 
hospice]) were analyzed as ﬁ rst-year costs and follow-up adjusted costs (per-patient-
per-month [PPPM]). All costs were compared using rank sum tests. RESULTS: The 
study identiﬁ ed 126 HCC cases and 126 controls: mean age 49 years, 51% male, 
mean follow-up months: 9.2 cases/11.9 controls, and deaths: 29.4% cases/1.6% 
controls. First-year costs were 1.5 to 8 times higher in cases versus controls (long-term 
care $3752 vs. $2554, ER $126 vs. $51, outpatient $4143 vs. $1412, inpatient 
$12,425 vs. $1595, all with P < 0.012). PPPM costs were 3 to 27 times higher in cases 
versus controls (long-term care $626 vs. $233, outpatient $884 vs. $119, ER $34 vs. 
$4, inpatient $3738 vs. $139, all with P < 0.001). Total costs were two times higher 
for HCC cases in the ﬁ rst year ($29,795 vs. $13,151, P < 0.001) and six times higher 
as PPPM ($6376 vs. $1125, P < 0.001). No patients had a sorafenib prescription. 
CONCLUSIONS: First-year medical care costs were substantially higher for the HCC 
patients, and even higher when adjusted for follow-up on a PPPM basis. Future thera-
pies that improve survival and disease control may enable payers to reduce monthly 
costs, and use the savings to treat other patients. 
PCN10
ESTIMATION OF THE HEALTH AND COST BURDEN OF HPV-RELATED 
DISEASES IN THAILAND
Termrungruanglert W1, Havanond P1, Khemapech N1, Lertmaharit S1, Pongpanich S1, 
Khorprasert C1, Kitsiripornchai S2, Jirakorbchaipong P2, Taneepanichskul S1
1Chulalongkorn University, Bangkok, Thailand; 2MSD (Thailand) Ltd., Bangkok, Thailand
BACKGROUND: Cervical cancer is the ﬁ rst leading female cancer, especially, in 
developing countries. The two available HPV vaccines protect against HPV types 
16/18 responsible for majority of cervical cancer. The quadrivalent vaccine also 
protects against HPV types 6/11 that cause majority of genital warts. It is important 
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to examine health and cost burden of HPV-related diseases to understand the potential 
impact of introducing HPV vaccine. OBJECTIVES: We aimed to evaluate the long-
term health and cost burden associated with cervical cancer, cervical intraepitherial 
neoplasia (CIN) and genital warts from health-care provider perspective in Thailand. 
METHODS: We developed a state-transition Markov model to simulate the epidemi-
ology of stages of cervical cancer, CIN and genital warts in a hypothetical cohort of 
100,000 12-year-old girls. Costs included diagnosis and treatment costs of HPV 
related diseases. Probabilities at each chance node in the model were derived from the 
Thailand health-care context. RESULTS: The highest incidence of CIN and genital 
warts was observed among women aged 20–30 years. For cervical cancer, the highest 
incidence was observed among women aged 45–55 years. Death rate was estimated 
at 2%, 8%, 84%, and 94% for cervical cancer stage IA1, IA2-IIA, IIB-IVA, and IVB, 
respectively. The estimated mean direct cost per patient with cervical cancer stage IA1, 
IA2-IIA, IIB-IVA, IVB, CIN1, CIN2/3 and genital warts were US$1277, US$3020, 
US$12,506, US$10,019, US$167, US$1551, and US$111, respectively. The overall 
lifetime costs were estimated at US$26.7 million for a cohort of 100,000 women, 
which corresponded to approximately US$132.0 million for the current entire cohort 
of 12-year-old girls in Thailand. CONCLUSIONS: HPV- related diseases impose 
signiﬁ cant health and cost burden in Thailand. The potential impact on HPV-related 
diseases of a national immunization program with HPV vaccine should be examined 
to inform the policy discussions around the HPV vaccination program in Thailand. 
PCN11
PREVENTION OF OXALIPLATIN HYPERSENSITIVITY REACTION AND 
COST SAVING
Huang SF, Chen CH, Chan AL
Chi Mei Medical Center, Tainan, Taiwan
OBJECTIVES: Hypersensitivity reactions have been reported in Oxaliplatin for the 
treatment of advanced colorectal cancer (mCRC). The reported incidence of hyper-
sensitivity reactions (HSRs) is approximately 12%, with 1–2% of patients developing 
grade 3 or 4 in severity which may postpone length of stay and incurred extra cost 
for the treatment of hypersensitivity reactions. METHODS: This is a retrospective 
observational study. Medical records of hospitalized patients with mCRC, who treated 
with FOLFOX regimen and occurred mild to severe HSRs were identiﬁ ed and 
reviewed by oncology pharmacist from January 2004 to February 2010. Direct 
medical cost for the treatment of HSRs and the extra days of hospitalization were 
calculated. We compared the difference of direct medical cost for patients whose 
oxaliplatin was discontinued (group A) and those oxaliplatin was continued (group 
B) for treating mCRC after the computer detected patients’ allergy and the signal was 
appeared on the screen of physician-order-entry-system. Student t test was used for 
data analysis. RESULTS: A total of 442 patients with the diagnosis of mCRC and 
had reported moderate to severe HSRs during the treatment of FOLFOX regimen 
through our computerized decision supporting system (patients allergy history alert 
system) were included in this study. Twenty-four of 442 patients reported mild to 
severe hypersensitivity reactions caused by oxaliplatin. The total direct medical costs 
for 24 patients were NT$864,352 dollars. The direct medical cost to manage HRSs 
in group A was higher than that in group B. CONCLUSIONS: Oxaliplatin induced 
severe hypersensitivity reaction is scare, but it may cause an extra direct medical costs 
if it is appearance. To develop a computerized alert signal is helpful and is likely to 
save costs. 
PCN12
COST-EFFECTIVENESS OF THE ONCOTYPE DX® ASSAY IN AUSTRALIA: 
AN EXPLORATORY ANALYSIS
O’Leary B1, Foteff C2, Byron K3, Chang C4, Chao C4, Ng C5, Skrzypczak S4
1Covance Pty Ltd, North Ryde, NSW, Australia; 2Covance Pty Ltd, North Ryde, NSW, 
Australia; 3Gribbles Pathology, Clayton, VIC, Australia; 4Genomic Health, Inc., Redwood City, 
CA, USA; 5Genomic Health, Inc., Hong Kong, HKSAR, Hong Kong
OBJECTIVES: Oncotype DX is a molecular diagnostic assay that measures quantita-
tive expression of 21 genes within a breast tumor sample. The result is reported as a 
recurrence score (RS) that correlates with the risk of 10-year recurrence. The potential 
cost impact on chemotherapy treatment and an exploratory cost utility analysis were 
undertaken from the Australian health-care system perspective. METHODS: Input on 
the proportion of patients treated with chemotherapy and treatment regimens were 
obtained from an expert panel and a supplementary survey of Australian clinicians 
(oncologists and surgeons, n = 12). Data on the proportion of patients who would 
forgo chemotherapy based on knowledge of the RS and the incidence and cost of 
adverse events were obtained from published literature. RESULTS: The clinician input 
indicated that 33% of node negative and 84% of node positive women receive adju-
vant chemotherapy on average. The most common treatments for node-negative 
patients were AC (anthracycline and cyclophosphamide) (77%) and FEC100 (ﬂ uoro-
uracil, epirubicin and cyclophosphamide) (16%) and for node-positive patients FEC-D 
(FEC plus docetaxel) (54%), AC + paclitaxel (26%) and TAC (docetaxel plus AC) 
(14%). Published switch rates away from chemotherapy are 20% for node negative 
and 24% for node positive patients. The cost saving due to a reduction in chemo-
therapy was estimated to be A$2264 per woman tested. After consideration for the 
cost of the assay (A$4200) and a published utility rate of 0.5, a A$/QALY gain was 
estimated at A$9986. CONCLUSIONS: Knowledge of the Oncotype DX RS has a 
cost-offset due to the reduction in chemotherapy and is likely to be cost-effective. 
These beneﬁ ts reﬂ ect the quality of life and survival beneﬁ ts of a more targeted 
approach to treatment decision-making. Further analysis is warranted to include the 
potential costs of relapse avoided by use of the assay and any patient indirect costs in 
Australia. 
PCN13
COST-BENEFIT ANALYSIS OF A 21-GENE RECURRENCE SCORE FOR 
EARLY STAGE BREAST CANCER IN SINGAPORE
de Lima Lopes G1, Chien R2, Hornberger J3
1Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School 
of Medicine, Singapore; 2Cedar Associates LLC, Menlo Park, CA, USA; 3Cedar Associates LLC 
and Stanford University, Menlo Park, CA, USA
BACKGROUND: Breast cancer represents a signiﬁ cant burden of illness worldwide. 
Cost of cancer management is a key policy concern. The adoption of 21-gene breast 
cancer recurrence score (RS) was projected to be cost-effective. OBJECTIVES: To 
assess cost-beneﬁ t of the 21-gene RS for lymph node negative, estrogen receptor posi-
tive early-stage breast cancer (ESBC) in Singapore from a patient’s perspective. 
METHODS: We adopted a validated Markov model to calculate the cost implications 
of RS for an early-stage breast cancer patient. The probability of individual’s risk of 
recurrence, chemotherapy beneﬁ ts and decision impact of RS were derived from exist-
ing studies. The model accounted for both direct and indirect costs associated with 
adjuvant chemotherapy. Direct costs included chemotherapy drugs, supportive care 
drugs, administration, and management of adverse events adjusted by incidence, and 
cost of recurrence. Indirect costs included productivity loss during chemotherapy and 
distant recurrence. Chemotherapy regimen distribution and costs were obtained from 
medical oncologists at a private and a public cancer centers in Singapore. RESULTS: 
The pretest probabilities of risk of recurrence per woman as low, intermediate or high 
were 49.8%, 30.3%, and 19.9%, respectively. The average direct potential savings 
per patient tested in Singapore Dollars (SGD) for chemotherapy drug, supportive care, 
management of AE and administration were $2942, $1077, $169, and $1340, respec-
tively. Per patient saving from productivity loss during treatment was $468. At manu-
facturer price, the model projects immediate realized savings of $430 with the 
adoption of the RS. The model also projects $1331 direct savings, and $2418 indirect 
savings from preventing distant recurrence. Multiple sensitivity analyses demonstrate 
the robustness of the savings with adoption of RS under a variety of conditions. 
CONCLUSIONS: For women with ESBC in Singapore, the RS is a cost-saving treat-
ment decision tool. 
PCN14
ADDITIONAL HEALTH AND ECONOMIC IMPACT OF THE BIVALENT 
VERSUS THE QUADRIVALENT HPV VACCINE IN TAIWAN: RESULTS OF A 
PREVALENCE-BASED MODEL
Ho T1, Van Enckevort PJ2, Demarteau N3
1GlaxoSmithKline, Taipei, Taiwan; 2GlaxoSmithKline Biologicals, Singapore; 3GlaxoSmithKline 
Biologicals, Wavre, Belgium
OBJECTIVES: Two human papillomavirus (HPV) vaccines currently exist: a bivalent 
targeting oncogenic high-risk HPV-16/18 and a quadrivalent targeting high-risk HPV-
16/18 and low-risk HPV-6/11. Based on data in their respective trials, the bivalent 
vaccine is likely to have higher efﬁ cacy against non-vaccine oncogenic HPV-types 
(cross protection). The quadrivalent has an additional effect against genital warts. The 
differences in the annual impact of both vaccines on precancerous lesions, genital 
warts (GW) and cervical cancer (CC) were evaluated. METHODS: A static prevalence-
based model was developed, which estimates the differences in lesions, GW, CC, and 
costs prevented between the two vaccines over a one-year period at steady state (i.e., 
when all women are vaccinated). The base case analysis was performed from a health-
care payer’s perspective, including only National Health Insurance covered costs. In 
addition, an analysis from a societal perspective was performed, including also indirect 
costs and out-of-pocket payments. Epidemiological and cost data were obtained from 
published sources. Efﬁ cacy ﬁ gures were based on the latest results from each vaccine’s 
respective clinical trial. Univariate sensitivity analyses were conducted, in which 
parameters were varied 20% up and down from the baseline value. RESULTS: Under 
this model, the bivalent vaccine would result in an additional reduction of 1486 
ASCUS; 1768 CIN1; 1230 CIN2/3 and 166 CC cases per year, while the quadrivalent 
vaccine would result in an additional 7726 GW cases prevented per year. The addi-
tional annual costs averted with the bivalent vaccine was estimated at US$ 1.3 million 
and US$ 1.9 million from a health-care payer’s and societal perspective, respectively. 
This outcome is most sensitive to cross protection ﬁ gures. CONCLUSIONS: Vaccina-
tion with the bivalent vaccine is expected to have a higher impact than the quadrivalent 
vaccine on the prevention of precancerous lesions and CC in Taiwan, and would lead 
to more cost averted. 
PCN15
COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS 
DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
Topibulpong N, Tanasanvimon S, Parinyanitikul N, Sriuranpong V
Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: To determine the cost-effectiveness of the second line treatment of 
advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI) comparing to docetaxel under health-care pro-
vider perspective. Only direct medical cost was considered. Outcomes included the 
patients’ survivals. METHODS: We collected data of aNSCLC patients treated at the 
Medical Oncology Unit during the year 2009 in a prospective manner. Patients were 
followed until death. Direct medical costs included medicine cost, laboratory cost, 
